Sequoia Financial Advisors LLC Buys 21,240 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Sequoia Financial Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,940 shares of the company’s stock after acquiring an additional 21,240 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $6,469,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $25,000. Cornerstone Planning Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 567.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after purchasing an additional 1,134 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the stock. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Leerink Partners began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They issued an “outperform” rating and a $45.00 price target on the stock. Barclays upped their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings cut shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.10.

Teva Pharmaceutical Industries Stock Up 1.8%

Shares of NYSE TEVA opened at $37.01 on Friday. The stock has a 50-day moving average price of $34.91 and a two-hundred day moving average price of $33.37. The company has a market cap of $43.13 billion, a price-to-earnings ratio of 61.68, a PEG ratio of 4.53 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a 12 month low of $18.21 and a 12 month high of $38.37. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion for the quarter. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.